Asthma Global Clinical Trials Review, H2, 2019 - ResearchAndMarkets.com

The "Asthma Global Clinical Trials Review, H2, 2019" clinical trials has been added to ResearchAndMarkets.com's offering.

The clinical trial report, Asthma Global Clinical Trials Review, H2, 2019 provides an overview of Asthma clinical trials scenario. This report provides top line data relating to the clinical trials on Asthma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Asthma to Respiratory Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Asthma to Respiratory Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Asthma Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Asthma
  • Nov 26, 2019: AB Science will host a live webcast on masitinib in severe asthma on December 2, 2019
  • Nov 08, 2019: Gossamer announces data presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019
  • Nov 07, 2019: AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
  • Oct 16, 2019: Grad student researches new drug to combat asthma
  • Oct 01, 2019: Nucala minimises exacerbations in eosinophilic asthma patients
  • Oct 01, 2019: Sosei Heptares notes the announcement of positive results from phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
  • Oct 01, 2019: Single-Inhaler Extrafine Triple Therapy of Inhaled Corticosteroid, Long-Acting B2-Agonist and Long-Acting Muscarinic Antagonist Therapy Improves Lung Function and Reduces Asthma Exacerbations
  • Sep 30, 2019: Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
  • Sep 30, 2019: Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
  • Sep 26, 2019: Pieris Pharmaceuticals and AstraZeneca present multiple ascending dose phase 1b data for inhaled IL4-Ra Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress
  • Sep 23, 2019: GlaxoSmithKline to present on Mepolizumab at ERS 2019
  • Sep 09, 2019: Theravance Biopharma reports positive results from phase 1 clinical trial of TD-8236, an investigational, lung-selective, inhaled Pan-Janus Kinase (JAK) inhibitor for inflammatory lung diseases
  • Clinical Trial Profile Snapshots

Companies Mentioned

  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • Merck & Co Inc
  • C. H. Boehringer Sohn AG & Co KG
  • Teva Pharmaceutical Industries Ltd
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Pamplona Capital Management LLP

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/d57dsw

View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005362/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900